Analytical Data
-
基因名
BIRC7
- Application
-
别名
BIRC7;KIAP;LIVIN;MLIAP;Baculoviral IAP repeat-containing Protein 7
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96CA5
-
表达区间
1-298aa
-
氨基酸序列
MGPKDSAKCL HRGPQPSHWA AGDGPTQERC GPRSLGSPVL GLDTCRAWDH VDGQILGQLR PLTEEEEEEG AGATLSRGPA FPGMGSEELR LASFYDWPLT AEVPPELLAA AGFFHTGHQD KVRCFFCYGG LQSWKRGDDP WTEHAKWFPS CQFLLRSKGR DFVHSVQETH SQLLGSWDPW EEPEDAAPVA PSVPASGYPE LPTPRREVQS ESAQEPGGVS PAEAQRAWWV LEPPGARDVE AQLRRLQEER TCKVCLDRAV SIVFVPCGHL VCAECAPGLQ LCPICRAPVR SRVRTFLS
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BIRC7, also known as Baculoviral IAP Repeat Containing 7, is a member of the Inhibitor of Apoptosis Protein (IAP) family, which plays a critical role in regulating apoptosis and cellular stress responses. The overexpression of BIRC7 has been implicated in various cancers, including melanoma and certain types of leukemia, due to its ability to inhibit caspase activity and prevent programmed cell death, thereby contributing to tumor cell survival and resistance to therapy. Understanding the structure and function of BIRC7 is essential for developing targeted therapies that can overcome its protective effects in cancer cells. The recombinant BIRC7 protein has been expressed and purified for research purposes, allowing scientists to investigate its interactions with other cellular proteins, its role in apoptotic pathways, and its potential as a therapeutic target. With advances in biotechnology, studying BIRC7's mechanisms can lead to novel approaches in cancer treatment, potentially improving patient outcomes by sensitizing tumors to chemotherapeutic agents through the disruption of its anti-apoptotic functions.
